- Autoimmune Disorders in Women Possibly Triggered by Seafood
- FDA Approves Noninvasive Colorrectal Cancer Test
- FDA Approves Limited Use of Drug for Ebola
- FDA Approves Edwards Lifesciences Corporation’s Sapien XT
- Lymphoseek Injections Approved by FDA for Prolonged Extended Use
- Orexigen Therapeutics’ Contrave Awaits FDA’s Nod
- FDA Expressed Concern on E-Cigarette Smoking after Increase in Complaint Rate
- E-Cigarette Marketing to Be Regulated by FDA Appealed As They Pose Serious Threat to the Youth
- FDA Goes Tough on Honey with Added Sweeteners
- Is Your Honey Adulterated?
First Ever FDA Approved Drug for Hemophilia B
- Updated: March 30, 2014
Biogen Idec have announced that the United States Food and Drug Administration has approved their drug ALPROLIX™ for the treatment of hemophilia B. This is a rare, chronic, genetic condition in which the ability of a person’s blood to clot is impaired. This can lead to recurrent and prolonged bleeding in a person. Treatment of this disorder can be done either at regular, scheduled intervals of time or they can be one as and when it is required. As per the NHF normal hemophilia B therapy requires prophylactic infusions for a minimum of twice a week.
“The FDA approval of ALPROLIX™ is a significant milestone for the hemophilia B community, and represents an important first step in our commitment to transform the care of people with hemophilia,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “ALPROLIX offers people with hemophilia B the ability to prevent or reduce bleeding episodes with prophylactic infusions starting at least a week apart. We believe this new therapy will help more people with hemophilia and their caregivers realize the benefits of this treatment approach.”
The approval of ALPROLIX™ is a significant milestone in the treatment of hemophilia B. For almost 17 years scientists have been trying to find a way to reduce the bleeding or even develop a method to have prolonged blood circulation throughout the body. “Hemophilia has a significant impact on people whom it affects, throughout their lives,” said Patrick F. Fogarty, M.D., (4) assistant professor of medicine at the Hospital of the University of Pennsylvania, and director, Penn Comprehensive Hemophilia and Thrombosis Program. “ALPROLIX addresses a critical need by allowing people with hemophilia B to maintain factor levels with prophylactic infusions once weekly or once every 10 days. We hope this will facilitate use of prophylactic therapy.”